User login
Key clinical point: A significant proportion of patients with migraine do not respond to ≥1 triptans, and this lack of response is associated with increased migraine severity and disability.
Major finding: Overall, 42.5%, 13.1%, 3.9%, and 0.6% of patients did not respond to ≥1, ≥2 triptans, ≥3 triptans, and ≥3 triptans including a subcutaneous formulation, respectively, with triptan non-responders vs responders having a significantly higher migraine frequency (P < .001), intensity (P < .05), and disability (P < .001).
Study details: This study evaluated 2284 patients with migraine using cross-sectional data from the German Migraine and Headache Society Headache Registry.
Disclosures: This study was supported by Projekt DEAL. Several authors declared serving as advisory boards members or consultants for or receiving travel or research grants or honoraria for consulting, lectures, advisory boards, adboards, and educational talks from various sources.
Source: Ruscheweyh R et al. Triptan non-response in specialized headache care: Cross-sectional data from the DMKG Headache Registry. J Headache Pain. 2023;24:135 (Oct 10). doi: 10.1186/s10194-023-01676-0
Key clinical point: A significant proportion of patients with migraine do not respond to ≥1 triptans, and this lack of response is associated with increased migraine severity and disability.
Major finding: Overall, 42.5%, 13.1%, 3.9%, and 0.6% of patients did not respond to ≥1, ≥2 triptans, ≥3 triptans, and ≥3 triptans including a subcutaneous formulation, respectively, with triptan non-responders vs responders having a significantly higher migraine frequency (P < .001), intensity (P < .05), and disability (P < .001).
Study details: This study evaluated 2284 patients with migraine using cross-sectional data from the German Migraine and Headache Society Headache Registry.
Disclosures: This study was supported by Projekt DEAL. Several authors declared serving as advisory boards members or consultants for or receiving travel or research grants or honoraria for consulting, lectures, advisory boards, adboards, and educational talks from various sources.
Source: Ruscheweyh R et al. Triptan non-response in specialized headache care: Cross-sectional data from the DMKG Headache Registry. J Headache Pain. 2023;24:135 (Oct 10). doi: 10.1186/s10194-023-01676-0
Key clinical point: A significant proportion of patients with migraine do not respond to ≥1 triptans, and this lack of response is associated with increased migraine severity and disability.
Major finding: Overall, 42.5%, 13.1%, 3.9%, and 0.6% of patients did not respond to ≥1, ≥2 triptans, ≥3 triptans, and ≥3 triptans including a subcutaneous formulation, respectively, with triptan non-responders vs responders having a significantly higher migraine frequency (P < .001), intensity (P < .05), and disability (P < .001).
Study details: This study evaluated 2284 patients with migraine using cross-sectional data from the German Migraine and Headache Society Headache Registry.
Disclosures: This study was supported by Projekt DEAL. Several authors declared serving as advisory boards members or consultants for or receiving travel or research grants or honoraria for consulting, lectures, advisory boards, adboards, and educational talks from various sources.
Source: Ruscheweyh R et al. Triptan non-response in specialized headache care: Cross-sectional data from the DMKG Headache Registry. J Headache Pain. 2023;24:135 (Oct 10). doi: 10.1186/s10194-023-01676-0